Specific Diagnostics is a Mountain View, CA–based developer of in vitro diagnostic systems for the detection and identification of microorganisms while they grow in culture. Led by CEO Dr. Paul Rhodes, the company has developed Reveal, a patented chemical sensor array technology platform that detects growth and quantifies antibiotic efficacy using automated instruments and disposables. The company says Reveal delivers antibiotic susceptibility results in hours instead of days. Specific Diagnostics received a $12.5M investment from Telegraph Hill Partners and intends to use the funds to commercialize its platform. The company will progress to clinical studies and prepare Reveal for the market in Europe and the United States. Specific also maintains offices in Cambridge, UK.

Total raised

$13M

Funding rounds

1

Latest round

Equity

Latest activity

Sep 2019